These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

885 related items for PubMed ID: 26293742

  • 1. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S, Panei P, Arcieri R, Germinario EA, Capuano A, Margari L, Chiarotti F, Curatolo P.
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [Abstract] [Full Text] [Related]

  • 2. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 3. A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy.
    Schein J, Cloutier M, Gauthier-Loiselle M, Catillon M, Xu C, Qu A, Lee F, Childress A.
    J Comp Eff Res; 2024 Sep; 13(9):e240089. PubMed ID: 39132746
    [Abstract] [Full Text] [Related]

  • 4. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y, Yang L, Stein MA, Cao Q, Wang Y.
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [Abstract] [Full Text] [Related]

  • 5. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
    Ozbaran B, Kose S, Yuzuguldu O, Atar B, Aydin C.
    World J Biol Psychiatry; 2015 May; 16(8):619-24. PubMed ID: 26223958
    [Abstract] [Full Text] [Related]

  • 6. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
    Ruggiero S, Rafaniello C, Bravaccio C, Grimaldi G, Granato R, Pascotto A, Sportiello L, Parretta E, Rinaldi B, Panei P, Rossi F, Capuano A.
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):415-22. PubMed ID: 23234585
    [Abstract] [Full Text] [Related]

  • 7. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY, Pan YL, Lin HY, Huang LW, Gau SS.
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [Abstract] [Full Text] [Related]

  • 8. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B, Karakaya E, Oztop DB.
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
    Arcieri R, Germinario EA, Bonati M, Masi G, Zuddas A, Vella S, Chiarotti F, Panei P, Italian Attention-Deficit/Hyperactivity Disorder Regional Reference Centers.
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):423-431. PubMed ID: 23362511
    [Abstract] [Full Text] [Related]

  • 10. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
    Pozzi M, Carnovale C, Mazhar F, Peeters GGAM, Gentili M, Nobile M, Radice S, Clementi E.
    J Clin Psychopharmacol; 2019 Dec; 39(4):386-392. PubMed ID: 31205193
    [Abstract] [Full Text] [Related]

  • 11. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [Abstract] [Full Text] [Related]

  • 12. Methylphenidate and atomoxetine treatment negatively affect physical growth indexes of school-age children and adolescents with attention-deficit/hyperactivity disorder.
    Deng L, Zhou P, Zhu L, Zhang Y, Yang T, Zhao Q, Chen J, Li T, Cheng Q, Chen L.
    Pharmacol Biochem Behav; 2021 Sep; 208():173225. PubMed ID: 34217783
    [Abstract] [Full Text] [Related]

  • 13. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, Kim BN, Ahn DH, Marquez-Caraveo ME, Gao H, Williams DW, Levine LR.
    Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Hollis C, Kovshoff H, McCarthy S, Nagy P, Sonuga-Barke E, Wong IC, Zuddas A, Rosenthal E, Buitelaar JK, ADDUCE consortium.
    CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
    [Abstract] [Full Text] [Related]

  • 15. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
    Chou TL, Chia S, Shang CY, Gau SS.
    Eur Neuropsychopharmacol; 2015 Dec; 25(12):2300-10. PubMed ID: 26409297
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of atomoxetine and methylphenidate for problematic online gaming in adolescents with attention deficit hyperactivity disorder.
    Park JH, Lee YS, Sohn JH, Han DH.
    Hum Psychopharmacol; 2016 Nov; 31(6):427-432. PubMed ID: 27859666
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [ADHD register: post-marketing evaluation of the benefit-risk profile of drugs and promotion of the appropriateness].
    Panei P, Arcieri R.
    Recenti Prog Med; 2013 Jun; 104(6):254-61. PubMed ID: 23801229
    [Abstract] [Full Text] [Related]

  • 19. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
    Fredriksen M, Peleikis DE.
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
    [Abstract] [Full Text] [Related]

  • 20. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP, Keating GM.
    Paediatr Drugs; 2009 Jan; 11(3):203-26. PubMed ID: 19445548
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.